strated that excess volumes of crystalloid solution in the perioperative period, and the associated positive fluid balance, are detrimental to recovery. 3 4 Colloids have not been shown to have a beneficial effect over crystalloids when used for fluid resuscitation in critical illness and the use of older generations of hydroxyethyl starch (HES) solutions with higher molecular weights and higher substitution ratios was associated with increased complications, including blood coagulation disorders and renal dysfunction. 5 6 The newer generations of HES certainly seem to have an improved safety profile as evidenced by two recent analyses, 7 8 but no clinical outcome benefit has been shown for their use in the perioperative period: indeed, a recent Cochrane review has recommended their use be limited to randomized controlled trials.
after colorectal surgery compared with a balanced crystalloid solution, when both products were given within a goal-directed protocol.
Methods

Study oversight
This trial was a double-blind, randomized controlled trial conducted in a single-centre hospital in the UK. The trial protocol was written by the investigators and approved by the Leeds (West) Research Ethics Committee (09/H1307/77) and the Medicines and Healthcare products Regulatory Agency. The trial was registered with Current Controlled Trials (ISRCTN41882213) and the European Union Drug Regulating Authorities Clinical Trials (EudraCT-2009-013872-29).
Written informed consent was obtained from all participants before randomization. Data and tissue samples were collected by trained research nurses or the investigators. The trial was conducted in accordance with GCP and monitored by an external agency.
Data management and statistical analysis plans were authorized by the sponsor before any data analysis or unblinding. The investigators remained blinded to group allocation until data had been validated and the database locked. The investigators performed all statistical analysis in accordance with the plan, and attest to the integrity of the data and the manuscript.
Financial support was in the form of an unrestricted grant from Fresenius Kabi who also supplied the study fluids free of charge. Fresenius Kabi had no input into the conduct of the trial, data analysis, or decision to submit the manuscript. The trial was adopted onto the National Institute for Health Research Clinical Research Network Portfolio.
No interim analysis was performed for this trial.
Screening and consent
Patients were screened for eligibilityat a surgical pre-assessment clinic where they underwent cardiopulmonary exercise testing (CPET) as part of their standard preoperative investigations to assess their functional status, and therefore perioperative risk. Patients more than 55 yr of age were eligible for the trial if their oxygen consumption at anaerobic threshold was ,14 ml kg
, thereby excluding the lowest risk patients. Inclusion and exclusion criteria are provided in Supplementary Table S1 . Randomization was performed using a 'block of 4' technique, and stratified according to whether the patient was deemed to be moderate or high risk on the basis of CPET. Patients were randomized to receive either 6% HES (130/0.4) in a balanced salt solution (Volulyte 6%, Fresenius Kabi, Bad Homburg, Germany) or balanced salt solution alone (Hartmann's, Fresenius Kabi) as their haemodynamic optimization fluid (HOF). Trial fluids were blinded to investigators by pharmacy staff placing an opaque, black wrapper over the 500 ml bag leaving the identical administration ports free.
Haemodynamic optimization protocol
Before induction of anaesthesia, patients had an i.v. cannula inserted into a forearm vein for administration of study fluid, and an arterial line sited in a radial artery. Haemodynamic variables were measured via a LiDCO Rapid monitor (LiDCO, Cambridge, UK). A 250 ml bolus of HOF was administered using a 50 ml syringe and the stroke volume response recorded. If the stroke volume increased by more than 10%, the bolus was repeated. No further bolus was given once the stroke volume failed to increase by more than 10%. After induction of anaesthesia, further boluses of HOF were administered during surgery to maintain a stroke volume variation (SVV) ,10%. For patients with dysrhythmias, the stroke volume was used to guide HOF administration in the same manner as the pre-induction protocol ( Supplementary Fig. S1 ).
HOF was administered up to a maximum of 50 ml kg 21 
Anaesthesia and postoperative management
Anaesthesia was induced with fentanyl (1-3 mg kg 21 ) and propofol (1-3 mg kg 21 ) and maintained with isoflurane or desflurane in oxygen-enriched air. Postoperative analgesia was provided with either a thoracic epidural or patient-controlled morphine boluses and discontinued at the discretion of the hospital Acute Pain Team. Dopexamine was started intraoperatively if there was evidence of tissue hypoperfusion (elevated lactate or base deficit) and if commenced was continued for 24 h after operation. Postoperative fluid management beyond the first 24 h was at the discretion of the clinical team. The commencement of enteral diet was also at the discretion of the clinical teams with all surgeons using the principles of enhanced recovery.
Perioperative monitoring
Patient haemodynamic status was monitored and recorded continuously throughout the intraoperative period and for 3 h after surgery. Arterial blood gas monitoring was performed at predefined intervals and systemic oxygen delivery calculated.
Thromboelastography subgroup
A subgroup of 37 consecutive patients had thromboelastography (TEG) performed (Haemonetics, Thromboelastograph, Haemostasis System, Middlesex, UK) to assess the effect of trial fluids on coagulation. Samples were obtained at baseline, 1 h into surgery, end of surgery, and 3 h after surgery.
Inflammatory marker subgroup A subgroup of 48 consecutive patients had serum inflammatory markers measured. Interleukin-6 (IL-6) and Interleukin-10 (IL-10) were measured before operation and at 1, 3, 6, and 24 h after operation (Luminex IS, Bio-Rad, Herts, UK). C-reactive protein (CRP) was measured before operation and on days 1, 3, 5, and 7 after operation (Cobas c501, Roche Diagnostics, West Sussex, UK).
Outcome measures
The primary outcome measure was the presence of gastrointestinal (GI) morbidity at day 5 after operation. This was defined as the inability to tolerate a full enteral diet either by mouth or via a feeding tube for any reason, including nausea, vomiting, abdominal distension, or ileus. This measure was recorded by blinded researchers using direct patient questioning and observing fluid balance charts, treatment charts, and the medical records. See Supplementary Table S2 for details of the Post-Operative Morbidity Survey (POMS).
Secondary outcome measures included the incidence of predefined major and minor complications during hospital admission, postoperative recovery as measured by the POMS, hospital length of stay, perioperative haemodynamic variables, use of additional inotropic support, measures of tissue perfusion (lactate and base deficit), the use of additional openlabel gelatine, changes in inflammatory markers, and changes in coagulation.
Statistical analysis
We determined that 202 patients were needed to detect a reduction in the incidence of GI morbidity on postoperative day 5 from 50% to 30% with a one-tailed power of 90% assuming an a-level of 0.05.
Patients assessed for eligibility n=407
Patients randomized n=206
Patients excluded, n=201
Did not meet inclusion criteria, n=72 Patients discontinued participation, n=0
Patients lost to follow-up, n=0
Patients discontinued participation, n=0
Patients included in analysis, n=104
Patients excluded from analysis, n=0
Patients included in analysis, n=98
Patients excluded from analysis, n=0 Crystalloid or colloid for goal-directed fluid therapy
In addition, 30 patients were needed to detect a 30% increase in reaction time (r time) on TEG with a power of 80% and an a-level of 0.05.
All data were analysed on an intention-to-treat basis. Missing data were coded as such-no imputations were used. Continuous data were analysed using mean differences and t-tests. Nonparametric data were analysed using the Mann-Whitney U-test.
Binary outcomes were compared using the x 2 tests or logistic regression. Odds ratios (ORs) and 95% confidence intervals were calculated when appropriate. The length of hospital stay was analysed using log-rank tests and the Kaplan-Meier curves. Areas under the curve were calculated for each patient for the temporal changes in inflammatory markers and compared with t-tests.
Results
A total of 206 patients were recruited from February 2010 to August 2012 (Fig. 1 ).
Functional capacity, and therefore perioperative risk, 10 11 as determined by CPET was similar between the two groups. There were no differences in other baseline characteristics (Tables 1  and 2 Table S3 ]. Given reported relationships between perioperative DO 2 and postoperative morbidity, outcomes are presented after adjustment for baseline DO 2 .
Compliance with the haemodynamic optimization protocol was good. Deviations are reported in Supplementary  Table S4 . Patients in the crystalloid group received more trial fluid during surgery and were more likely to require Geloplasma [OR¼4.44 (2.12 -9.30)]. Subjects in the HES group received more fluid in the postoperative period, and when they did require Geloplasma, a greater volume was needed. Total fluid administered within the 24 h period was greater in the crystalloid group. After adjustment for DO 2 , there was no significant difference between the groups in the odds of a patient requiring a blood transfusion either intraoperatively [adjusted OR for the HES group¼2.74 (0.94-8.01)] or in the entire trial period [adjusted OR¼2.03 (0.88-4.68)]. There was no difference between the groups in the volumes of blood transfused within the trial period.
The overall fluid balance 24 h from the start of surgery was greater in the crystalloid group (Table 3) .
There was no significant difference in the number of patients who required vasopressors to maintain arterial pressure during surgery, or in the doses required (Supplementary  Table S5 ).
After the initial bolus of trial fluid, the haemoglobin level in the HES group was lower than that in the crystalloid group. There were no other significant differences in the haemodynamic variables between the two groups (Supplementary Table S3 ).
Primary outcome
The number of subjects unable to tolerate a full enteral diet on postoperative day 5 was 30% in the HES group and 32% in the crystalloid group [adjusted OR¼0.96 (0.52-1.77)]. The mean time to oral diet was 2.8 days in both groups (P¼0.61). The time to first bowel movement was also similar between the groups-3.7 days in the crystalloid group and 4.0 days in the colloid group (P¼0.62).
No significant differences were seen between the treatment groups in the number of patients who developed postoperative complications (Table 4, definitions of complicationsSupplementary Table S6) .
Characteristics of patients in whom complications occurred compared with those in whom they did not are shown in Supplementary Table S7 . No difference in postoperative morbidity was seen between the groups at any point ( Supplementary Fig.  S2 ). There were no significant outcome differences between the groups when analysed according to the risk group (Supplementary Table S8 ).
Five patients in the HES group and two patients in the crystalloid group died [adjusted OR¼1.99 (0.37 -10.78)]. There was little difference in hospital length of stay between the groupsa median of 8 days in the crystalloid group and 9 days in the HES group (log-rank test, P¼0.74) (Supplementary Fig. S3 ).
There were no significant differences between the groups in measured inflammatory markers at any point, nor was there any difference in IL-6 between those patients who suffered complications and those who did not ( Supplementary Fig. S4 ).
No changes were seen in coagulation with HES therapy except a reduction in the maximum amplitude (MA) at the end of surgery and at 3 h after operation when compared with baseline. MA values did not fall outside the normal range. Evidence of increased coagulation (from baseline) was seen in the crystalloid group in all the variables with the exception of MA which remained unchanged (Supplementary Fig. S5 ).
Discussion
In this double-blind randomized controlled trial, no clinical benefit was seen from using HES for routine haemodynamic optimization in the perioperative period compared with crystalloid. This is in concordance with recently published data which demonstrated either no benefit or harm in the routine use of similar products in patients with established critical illness. 12 13 Critically ill patients may have damaged vascular endothelium and colloid may redistribute into the interstitium causing harm. 14 The use of HES in elective surgical patients whose vascular endothelium is intact may therefore have benefits in terms of restricting the volume of fluid needed to achieve haemodynamic optimization. Despite HES patients requiring less fluid than those in the crystalloid group, there was no clinical benefit. We chose the GI domain of the POMS as our primary outcome as it is a reliable and easily measured outcome parameter and relevant to the surgical population being studied. Rates for GI morbidity at day 5 after operation have previously been reported ranging from 26% to 65%. 15 -17 Inter-observer reliability is good in this domain of the POMS with good agreement in both validation studies published to date, k¼0.66 and k¼0.71. In one of these studies, by Grocott and colleagues, 16 there was a mean increase in hospital length of stay of 4.3 days (P¼0.002) in those patients with GI morbidity at day 5 after operation (65.3% of the cohort). Davies and colleagues, Hartmann's procedure 7 6 Pan proctocolectomy 1 3
Reversal of Hartmann's procedure 38 (19) 37 (22) POSSUM-predicted mortality (%)
8 (7) 9 (9) P-POSSUM predicted mortality (%)
3 (4) 4 (5) Other interventions
Epidural analgesia 92% 91%
Laparoscopic procedure 24% 17%
Drains in situ after surgery 46% 56% Dopexamine infusion 5% 3%
Crystalloid or colloid for goal-directed fluid therapy in another POMS validation study performed at our institution, demonstrated a 5 day increase in length of stay (P,0.001) in the 32% of patients unable to tolerate an enteral diet at day 5. Two trials performed at our institution demonstrated significantly different GI morbidity rates at day 5 after operation after major intra-abdominal surgery (63% vs 26%). Different fluid therapy regimes were used; in the study by Davies and colleagues, 15 a quicker return of GI function was observed after the administration of goal-directed HES intraoperatively, without any additional crystalloid therapy, whereas in the study by Stone and colleagues, 18 a similar volume of colloid was administered but patients also received an additional 2000 ml of crystalloid during surgery. We hypothesized that this extra volume of crystalloid may have been responsible for the increase in morbidity. Kimberger and colleagues 2 demonstrated a higher tissue oxygen tension and perfusion at the colonic anastomoses in a porcine model receiving goaldirected colloid rather than goal-directed crystalloid and work by both Brandstrup and colleagues 3 and Nisanevich and colleagues 4 demonstrated worse postoperative outcomes as the administered perioperative fluid volumes increased, and in particular as the crystalloid volume increased. Both these studies were unblinded and the results of our study do not support this hypothesis. While patients in the crystalloid group received significantly more fluid, and had a greater 24 h fluid balance, it does not seem to have had any detrimental effect on postoperative outcomes.
Only one previous study has compared colloid with crystalloid in the elective perioperative setting; 19 however, numbers were small, and the trial lacked power to detect differences in complications between the groups. This is the first trial demonstrating that crystalloid alone given in a goal-directed manner is safe even in relatively large volumes. We used SVV as measured by the LiDCO Rapid to guide fluid therapy. This parameter has been used in our institution for several years with good outcomes for both routine clinical practice and as part of a previous study. 15 While the bulk of the evidence supporting haemodynamic optimization in the perioperative setting has used oesophageal Doppler-based algorithms, emerging evidence would suggest that the use of SVV is a valid and beneficial option. 20 -23 Traditionally, clinicians have been taught that crystalloid solutions distribute across the extracellular compartment but that colloids are maintained intravascularly due to their molecular size. This led to a perception that three times more crystalloid as colloid would be required to achieve similar haemodynamic effects.
In this trial, administration of colloid to crystalloid was in a ratio of 1:1.6 implying that significantly smaller volumes of crystalloid are needed to optimize the circulation than the three-fold increase that was previously proposed. James and colleagues 24 investigated the role of crystalloids and colloids in trauma resuscitation and found a ratio of colloid to crystalloid of 1:1.5 and similarly, the SAFE study 25 demonstrated a Table 3 Perioperative fluid administration and balance. Data presented as medians (IQRs). *P,0.05, **P,0.01, ***P,0.001 The magnitude of the systemic inflammatory response after surgery has been shown to be related to the severity of surgical insult. 26 IL-6 is an inflammatory cytokine released predominantly from the colonic circulation at the time of surgery and elevated levels have been associated with worse outcomes. 27 In this study, we did not show any difference between the circulating levels of IL-6, IL-10, or CRP between the two groups. While the administration of i.v. fluid in a goal-directed manner has been demonstrated to reduce the peak inflammatory cytokine levels, 28 it does not appear to matter whether crystalloid or HES is used to achieve these goals.
We undertook this part of the study with reference to work that has since been retracted from the literature that demonstrated a reduction in pro-inflammatory cytokines with HES administration. 29 Our data do not support the hypothesis that the use of HES maintains the splanchnic circulation more effectively and thus reduces inflammation. Several studies to date have demonstrated both in vitro and in vivo enhancement of coagulation with crystalloid administration. 30 31 In keeping with this literature, we demonstrated an increase in clot formation time and the MA (a measure of platelet function) that was not apparent in the HES group. No actual coagulopathy was induced with the administration of HES and no increase in thrombotic events was seen in the crystalloid group. It has been suggested that rapid haemodilution causes an enhancement of coagulation per se but that this enhancement in the HES group is offset by the inhibition of platelet aggregation by starch molecules. 32 The strengths of this trial include its low risk of bias. Blinding was maintained throughout and all other perioperative variables were tightly controlled in an attempt to reduce confounding. We studied a homogenous population of high to moderate-risk patients in an attempt to minimize 'noise' that would be generated by the inclusion of low-risk patients who suffer little postoperative morbidity. The fact that the group was so homogenous means that the results should be extrapolated to other surgical specialities with caution.
In summary, we have demonstrated that HES confers no benefit over crystalloids when used for routine haemodynamic optimization within a goal-directed protocol in the moderate to high-risk colorectal surgical patient. Lower volumes may be required to reach haemodynamic endpoints with HES, but targeted crystalloid administration would appear to be an effective alternative.
